Tocilizumab (anti-IL-6R)

製品コードA2012 別名: MRA

For research use only.
Not for use in humans.

Tocilizumab is a humanized monoclonal antibody that binds to the interleukin-6 receptor, MW: 148 KD.

サイズ 価格(税別)  
JPY 103700
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(15)

質量管理及び製品安全説明書

IL Receptor阻害剤の選択性比較

生物活性

製品説明 Tocilizumab is a humanized monoclonal antibody that binds to the interleukin-6 receptor, MW: 148 KD.
ターゲット
IL-6R [1]
()
体外試験

Tocilizumab (anti-IL-6R) inhibits the binding of IL-6 to its receptors, and thus reduces the cytokines pro-inflammatory activity by competing for both the soluble and membrane-bound forms of the human IL-6 receptor. The inhibitory profile of anti-IL-6R mAb Tocilizumab is independent of membrane-bound IL-6R expression[1]. Tocilizumab has anticancer potency via apoptosis induction as an agonistic IL-6R regulator. It has also been demonstrated that tocilizumab has an anti-proliferative effect on glioma cells via inhibition of the JAK-STAT3 pathway. Tocilizumab exhibits a significant growth inhibition in NSCLC cells (H460, A549, H1299 and H358), with proliferation significantly decreased by approximately 40% in A549 cells. Tocilizumab does not alter the levels of the ERK1/2, STAT3, NFκB and phosphorylated ERK1/2 and STAT3 proteins, but this antibody does considerably increase the expression of phosphorylated NFκB in NSCLC cells[2]. Tocilizumab significantly inhibits expression of both IL-8 and MMP-9, known as the major angiogenic factors[3].

体内試験 A series of clinical studies has shown that inhibition of IL-6 signaling by tocilizumab is therapeutically effective in rheumatoid arthritis, juvenile idiopathic arthritis, Castleman's disease, and Crohn's disease. In all of these diseases, tocilizumab ameliorates inflammatory manifestations, and normalizes acute phase protein levels. Tocilizumab as a monotherapy and in combination, such as with methotrexate in case of rheumatoid arthritis, seems to be well tolerated. Tocilizumab markedly decreases the number of invaded capillary vessels in tumors. In addition, tocilizumab shows almost no effect on mitogenic rate and apoptosis of tumor cells[3].

お薦めの試験操作(参考用のみ)

細胞試験:
- 合併
  • Objective: To validate that IL-6 signaling is essential for TAM (tumor-associated macrophages)-enhanced CSC (cancer stem cells) function
    Cells: HepG2 cell lines, TAMs isolated from HCCs (hepatocellular carcinoma)
    Concentrations: 5 μg/ml
    Incubation Time: 72 h
    Method: For co-culture experiments, 12-well Transwell chambers were used with 2×105 HepG2 or Hep3B cells seeded in the lower chamber one day before co-culture and either 5×105 or 1×106 TAMs added in the upper chamber. Tocilizumab or human IgG antibody were added in indicated experiments to selected wells. After 24 to 72 hours, HCC cells and CD14+ TAM cells were collected separately for analysis.
    Reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253315/

    Objective: Effect of tocilizumab on the growth of Lung Cancer Cells
    Cells: human-derived HARA-B cells
    Concentrations: 1, 10, 100 ng/ml
    Incubation Time: 48 h
    Method: HARA-B cells were cultured for 24 h in DMEM, then in serum-free DMEM for 24 h and then for 48 h in HACM (serum-free), with or without tocilizumab (1, 10, and 100 ng/mL) or human IgG as the negative control.
    Reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565278/

    Tocilizumab can apply to immunodeficient mice (eg: SCID mice), Non-immunodeficient mice (eg: DBA/1J mice), various cancer cell lines and other in vitro assays (Only for Reference)

動物試験:
- 合併
  • Objective: Tocilizumab inhibits the growth of mucoepidermoid carcinomas
    Animal Models: Female severe combined immunodeficient (SCID) mice were transplanted with Michigan-Human Mucoepidermoid Carcinoma cells
    Formulation: --
    Dosages: 5 mg/kg
    Administration: i.p.
    Reference: https://www.ncbi.nlm.nih.gov/pubmed/26287605

    Objective: Therapeutic assessment of Tocilizumab-Alendronate Conjugate in collagen-induced arthritis (CIA) mice model
    Animal Models: DBA/1j mice were injected with CII which emulsified in CFA or IFA
    Formulation: PBS
    Dosages: 0.8 mg/kg
    Administration: Locally injected on the arthritic ankle joints
    Reference: https://www.ncbi.nlm.nih.gov/pubmed/28107624

    Tocilizumab can apply to immunodeficient mice (eg: SCID mice), Non-immunodeficient mice (eg: DBA/1J mice), various cancer cell lines and other in vitro assays (Only for Reference)

製品説明

CAS No. ‎375823-41-9
Formulation PBS buffer, pH 7.2
Isotype Human IgG1
Source CHO cells
Storage Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

技術サポート

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    How to store the antibody?

  • 回答:

    Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.

相関IL Receptor製品

Tags: Tocilizumab (anti-IL-6R)を買う | Tocilizumab (anti-IL-6R) ic50 | Tocilizumab (anti-IL-6R)供給者 | Tocilizumab (anti-IL-6R)を購入する | Tocilizumab (anti-IL-6R)費用 | Tocilizumab (anti-IL-6R)生産者 | オーダーTocilizumab (anti-IL-6R) | Tocilizumab (anti-IL-6R)化学構造 | Tocilizumab (anti-IL-6R)分子量 | Tocilizumab (anti-IL-6R)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID